首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1580篇
  免费   149篇
  国内免费   96篇
  2023年   9篇
  2022年   14篇
  2021年   65篇
  2020年   39篇
  2019年   60篇
  2018年   54篇
  2017年   48篇
  2016年   72篇
  2015年   92篇
  2014年   104篇
  2013年   102篇
  2012年   97篇
  2011年   97篇
  2010年   83篇
  2009年   67篇
  2008年   68篇
  2007年   76篇
  2006年   56篇
  2005年   62篇
  2004年   71篇
  2003年   68篇
  2002年   52篇
  2001年   28篇
  2000年   34篇
  1999年   26篇
  1998年   18篇
  1997年   10篇
  1996年   14篇
  1993年   9篇
  1992年   14篇
  1991年   7篇
  1990年   10篇
  1989年   12篇
  1987年   14篇
  1986年   13篇
  1985年   19篇
  1984年   6篇
  1983年   6篇
  1981年   8篇
  1980年   6篇
  1979年   7篇
  1978年   7篇
  1977年   8篇
  1976年   10篇
  1974年   10篇
  1973年   9篇
  1970年   8篇
  1969年   6篇
  1968年   6篇
  1966年   6篇
排序方式: 共有1825条查询结果,搜索用时 84 毫秒
41.
42.
Although aging and senescence have been extensively studied in the past few decades, however, there is lack of clinical treatment available for anti‐aging. This study presents the effects of berberine (BBR) on the aging process resulting in a promising extension of lifespan in model organisms. BBR extended the replicative lifespan, improved the morphology, and boosted rejuvenation markers of replicative senescence in human fetal lung diploid fibroblasts (2BS and WI38). BBR also rescued senescent cells with late population doubling (PD). Furthermore, the senescence‐associated β‐galactosidase (SA‐β‐gal)‐positive cell rates of late PD cells grown in the BBR‐containing medium were ~72% lower than those of control cells, and its morphology resembled that of young cells. Mechanistically, BBR improved cell growth and proliferation by promoting entry of cell cycles from the G0 or G1 phase to S/G2‐M phase. Most importantly, BBR extended the lifespan of chemotherapy‐treated mice and naturally aged mice by ~52% and ~16.49%, respectively. The residual lifespan of the naturally aged mice was extended by 80%, from 85.5 days to 154 days. The oral administration of BBR in mice resulted in significantly improved health span, fur density, and behavioral activity. Therefore, BBR may be an ideal candidate for the development of an anti‐aging medicine.  相似文献   
43.
44.
Dy3+‐doped Y3Al5O12 phosphors were prepared at a relatively low temperature using molten salt synthesis. The phase of the prepared Dy3+‐doped Y3Al5O12 phosphors was confirmed using X‐ray powder diffraction. Results indicated that Dy3+ doping did not change the Y3Al5O12 phase. Following excitation at 352 nm, emission spectra of the Dy3+‐doped Y3Al5O12 phosphors consisted of blue, yellow, and red emission bands. The influence of Dy3+ concentration and excitation wavelength on emission was investigated. The ratio of yellow light to blue light varied with change in Dy3+ doping concentration, due to changes in the structure around Dy3+. Emission intensities also changed when the excitation wavelength was changed. This variation is luminescence generated a system for tunable white light for Dy3+‐doped Y3Al5O12 phosphors.  相似文献   
45.
46.
This paper aims to illustrate the clinical characteristics, hematological findings, and blood transfusion information of Coronavirus disease 2019 (COVID-19) patients. Twenty-three COVID-19 patients were treated and transfused with blood products in Wuhan First Hospital from February 12 to March 20, 2020. The patients were divided into a survivor group and a non-survivor group, respectively, according to whether the patient had been discharged or died. The results demonstrated at the time of initial blood transfusion, that the non-survivor group possessed a lower platelet (PLT) than that of the survivor group (P<0.001), and PLT were below the normal range in 6 (85.7%) non-survivor group and in 2 (12.5%) survivor group (P<0.01). Over half of these patients had abnormalities in fibrinogen (FIB), activated partial thromboplastin time (APTT), prothrombin time (PT), and international normalized ratio (INR), but no significant difference was found between the non-survivor group and survivor group. The non-survivor group had a dramatically higher D-Dimers and disseminated intravascular coagulation (DIC) scores than those of the survivor group (P<0.01). Six (85.7%) non-survivors but none of the survivors had a DIC score greater than 6 (P<0.001). Fifteen (93.8%) survivors and 2 (28.6%) non-survivors were transfused with RBC (P<0.01). The non-survivors (5/7) possessed a higher proportion for using AP than the survivors (2/16). The study suggests that COVID-19 patients who undergo blood transfusion usually possess coagulation dysfunction, and DIC may be closely related to deteriorating clinical outcomes.  相似文献   
47.
Environmental Biology of Fishes - Eel movement patterns have been frequently studied to learn about their movements within the fresh- and brackish waters of the same river before their spawning...  相似文献   
48.
49.
营养元素含量及化学计量比可反映植物器官营养元素的分配及互作关系,亦可反映其营养利用效率及生长环境的养分限制状况。以青桐(Firmiana platanifolia)幼苗为材料,分析4种不同光强(全光照,50%、75%和95%遮荫)对青桐幼苗生长,C、N、P、K含量及其化学计量特征的影响。结果表明:遮荫对青桐幼苗的生长性状、生物量、元素含量和积累量及化学计量比均有显著影响(P<0.05)。苗高和比叶面积随遮荫强度增加而升高,而地径和粗壮度随遮荫强度增加而减小。总生物量在75%遮荫下最大,在95%遮荫下最小。在各遮荫处理下,叶片C、N、P、K含量均大于根和茎,且N含量顺序为叶>根>茎,K含量顺序为叶>茎>根。C、P、K积累量随遮荫强度增大而增加,在75%遮荫下达到最大值,而在95%遮荫下达到最小值。青桐幼苗C∶N和C∶P呈现出相同的变化趋势,随遮荫强度变大先增加后减小,均在50%遮荫下达最大值。青桐各器官N∶P远低于14,即青桐幼苗在不同遮荫条件下的生长严重受N限制。这些结果说明,遮荫可调节青桐幼苗在不同光环境中的养分积累与分配,进而影响生物量。因此,青桐苗期培育宜选75%遮荫,有助于苗高、比叶面积、生物量、养分含量和积累量的增加,而过度遮荫可抑制幼苗生长发育。  相似文献   
50.
目的探讨内生Bacillus svelezensis HBB5菌株发酵宿主植物盾叶薯蓣产薯蓣皂苷元的能力。方法接种内生B.svelezensis HBB5及B.subtilis ATCC 6633菌株(0.35×10~8 CFU/mL)至含盾叶薯蓣地下茎组织的液体培养基,32℃、165~185 r/min连续发酵108 h,检测发酵液细菌、pH、淀粉、麦芽糖、葡萄糖、淀粉酶(α-amylase)及薯蓣皂苷元溶出率等指标。结果内生B.svelezensis HBB5菌株有较强的酸、碱耐受力[pH(4.8±0.2)~(8.4±0.2)],相比B.subtilis ATCC 6633[pH(5.2±0.2)~(8.7±0.2)]差异不明显;前者达峰值生长量(60×10~(8±2) CFU/mL)明显高于后者(32×10~(8±2) CFU/mL)。发酵36~60 h时,B.svelezensis HBB5、B.subtilis ATCC 6633菌株发酵液的淀粉、麦芽糖、葡萄糖浓度达峰值,分别为(37.41±3.12)、(27.83±2.14)ng/mL,(21.06±1.25)、(16.54±1.08)ng/mL,(54.33±3.12)、(36.65±2.10)ng/mL,前者均高于后者。同时,B.svelezensis HBB5菌株维持高的α-amylase酶活性及薯蓣皂苷元溶出率。结论内生B.svelezensis HBB5菌株拥有较强的耐酸碱、降解淀粉、提高薯蓣皂苷元溶出的能力,为工业生产薯蓣皂苷元提供了一个新的方法。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号